Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin.

@article{Millikan2001GemcitabineMO,
  title={Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin.},
  author={Randall E. Millikan and William Plunkett and Terry L. Smith and Dallas L Williams and Christopher J. Logothetis},
  journal={Cancer},
  year={2001},
  volume={92 1},
  pages={194-9}
}
BACKGROUND The authors investigated the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) associated with the addition of a biomodulating dose of gemcitabine to an established regimen of ifosfamide and doxorubicin as part of a program to explore the potential of low-dose gemcitabine to modulate the activity of alkylating agents. METHODS A Phase I trial was carried out in a population of patients with bladder or pelvic carcinoma for whom no standard therapy was available. Doses of… CONTINUE READING
6 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…